#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Machine learning identifies unaffected first-degree relatives with functional network patterns and cognitive impairment similar to those of schizophrenia patients Schizophrenia (SCZ) patients and their unaffected first-degree relatives (FDRs) share similar functional neuroanatomy.
1-1	0-7	Machine	_
1-2	8-16	learning	_
1-3	17-27	identifies	_
1-4	28-38	unaffected	_
1-5	39-51	first-degree	_
1-6	52-61	relatives	_
1-7	62-66	with	_
1-8	67-77	functional	_
1-9	78-85	network	_
1-10	86-94	patterns	_
1-11	95-98	and	_
1-12	99-108	cognitive	_
1-13	109-119	impairment	_
1-14	120-127	similar	_
1-15	128-130	to	_
1-16	131-136	those	_
1-17	137-139	of	_
1-18	140-153	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-19	154-162	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-20	163-176	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-21	177-178	(	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-22	179-182	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-23	183-184	)	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-24	185-193	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-25	194-197	and	_
1-26	198-203	their	_
1-27	204-214	unaffected	_
1-28	215-227	first-degree	_
1-29	228-237	relatives	_
1-30	238-239	(	_
1-31	240-244	FDRs	_
1-32	245-246	)	_
1-33	247-252	share	_
1-34	253-260	similar	_
1-35	261-271	functional	_
1-36	272-284	neuroanatomy	_
1-37	285-286	.	_

Text=However, it remains largely unknown to what extent unaffected FDRs with functional neuroanatomy patterns similar to patients can be identified at an individual level.
2-1	287-294	However	_
2-2	295-296	,	_
2-3	297-299	it	_
2-4	300-307	remains	_
2-5	308-315	largely	_
2-6	316-323	unknown	_
2-7	324-326	to	_
2-8	327-331	what	_
2-9	332-338	extent	_
2-10	339-349	unaffected	_
2-11	350-354	FDRs	_
2-12	355-359	with	_
2-13	360-370	functional	_
2-14	371-383	neuroanatomy	_
2-15	384-392	patterns	_
2-16	393-400	similar	_
2-17	401-403	to	_
2-18	404-412	patients	_
2-19	413-416	can	_
2-20	417-419	be	_
2-21	420-430	identified	_
2-22	431-433	at	_
2-23	434-436	an	_
2-24	437-447	individual	_
2-25	448-453	level	_
2-26	454-455	.	_

Text=In this study, we used a multivariate pattern classification method to learn informative large-scale functional networks (FNs) and build classifiers to distinguish 32 patients from 30 healthy controls and to classify 34 FDRs as with or without FNs similar to patients.
3-1	456-458	In	_
3-2	459-463	this	_
3-3	464-469	study	_
3-4	470-471	,	_
3-5	472-474	we	_
3-6	475-479	used	_
3-7	480-481	a	_
3-8	482-494	multivariate	_
3-9	495-502	pattern	_
3-10	503-517	classification	_
3-11	518-524	method	_
3-12	525-527	to	_
3-13	528-533	learn	_
3-14	534-545	informative	_
3-15	546-557	large-scale	_
3-16	558-568	functional	_
3-17	569-577	networks	_
3-18	578-579	(	_
3-19	580-583	FNs	_
3-20	584-585	)	_
3-21	586-589	and	_
3-22	590-595	build	_
3-23	596-607	classifiers	_
3-24	608-610	to	_
3-25	611-622	distinguish	_
3-26	623-625	32	_
3-27	626-634	patients	_
3-28	635-639	from	_
3-29	640-642	30	_
3-30	643-650	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-31	651-659	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-32	660-663	and	_
3-33	664-666	to	_
3-34	667-675	classify	_
3-35	676-678	34	_
3-36	679-683	FDRs	_
3-37	684-686	as	_
3-38	687-691	with	_
3-39	692-694	or	_
3-40	695-702	without	_
3-41	703-706	FNs	_
3-42	707-714	similar	_
3-43	715-717	to	_
3-44	718-726	patients	_
3-45	727-728	.	_

Text=Four informative FNs were identified based on a training cohort – the cerebellum, default mode network (DMN), ventral fronto-temporal network, and posterior DMN with parahippocampal gyrus – and pattern classifiers built upon these FNs achieved a correct classification rate of 83.9% (sensitivity 87.5%, specificity 80.0%, and area under the ROC [AUC] 0.914) estimated based on leave-one-out cross-validation for the training cohort and a correct classification rate of 77.5% (sensitivity 72.5%, specificity 82.5%, and AUC 0.811) for an independent validation cohort.
4-1	729-733	Four	_
4-2	734-745	informative	_
4-3	746-749	FNs	_
4-4	750-754	were	_
4-5	755-765	identified	_
4-6	766-771	based	_
4-7	772-774	on	_
4-8	775-776	a	_
4-9	777-785	training	_
4-10	786-792	cohort	_
4-11	793-794	–	_
4-12	795-798	the	_
4-13	799-809	cerebellum	_
4-14	810-811	,	_
4-15	812-819	default	_
4-16	820-824	mode	_
4-17	825-832	network	_
4-18	833-834	(	_
4-19	835-838	DMN	_
4-20	839-840	)	_
4-21	841-842	,	_
4-22	843-850	ventral	_
4-23	851-866	fronto-temporal	_
4-24	867-874	network	_
4-25	875-876	,	_
4-26	877-880	and	_
4-27	881-890	posterior	_
4-28	891-894	DMN	_
4-29	895-899	with	_
4-30	900-915	parahippocampal	_
4-31	916-921	gyrus	_
4-32	922-923	–	_
4-33	924-927	and	_
4-34	928-935	pattern	_
4-35	936-947	classifiers	_
4-36	948-953	built	_
4-37	954-958	upon	_
4-38	959-964	these	_
4-39	965-968	FNs	_
4-40	969-977	achieved	_
4-41	978-979	a	_
4-42	980-987	correct	_
4-43	988-1002	classification	_
4-44	1003-1007	rate	_
4-45	1008-1010	of	_
4-46	1011-1015	83.9	_
4-47	1016-1017	%	_
4-48	1018-1019	(	_
4-49	1020-1031	sensitivity	_
4-50	1032-1036	87.5	_
4-51	1037-1038	%	_
4-52	1039-1040	,	_
4-53	1041-1052	specificity	_
4-54	1053-1057	80.0	_
4-55	1058-1059	%	_
4-56	1060-1061	,	_
4-57	1062-1065	and	_
4-58	1066-1070	area	_
4-59	1071-1076	under	_
4-60	1077-1080	the	_
4-61	1081-1084	ROC	_
4-62	1085-1086	[	_
4-63	1087-1090	AUC	_
4-64	1091-1092	]	_
4-65	1093-1098	0.914	_
4-66	1099-1100	)	_
4-67	1101-1110	estimated	_
4-68	1111-1116	based	_
4-69	1117-1119	on	_
4-70	1120-1133	leave-one-out	_
4-71	1134-1150	cross-validation	_
4-72	1151-1154	for	_
4-73	1155-1158	the	_
4-74	1159-1167	training	_
4-75	1168-1174	cohort	_
4-76	1175-1178	and	_
4-77	1179-1180	a	_
4-78	1181-1188	correct	_
4-79	1189-1203	classification	_
4-80	1204-1208	rate	_
4-81	1209-1211	of	_
4-82	1212-1216	77.5	_
4-83	1217-1218	%	_
4-84	1219-1220	(	_
4-85	1221-1232	sensitivity	_
4-86	1233-1237	72.5	_
4-87	1238-1239	%	_
4-88	1240-1241	,	_
4-89	1242-1253	specificity	_
4-90	1254-1258	82.5	_
4-91	1259-1260	%	_
4-92	1261-1262	,	_
4-93	1263-1266	and	_
4-94	1267-1270	AUC	_
4-95	1271-1276	0.811	_
4-96	1277-1278	)	_
4-97	1279-1282	for	_
4-98	1283-1285	an	_
4-99	1286-1297	independent	_
4-100	1298-1308	validation	_
4-101	1309-1315	cohort	_
4-102	1316-1317	.	_

Text=The classification scores of the FDRs and patients were negatively correlated with their measures of cognitive function.
5-1	1318-1321	The	_
5-2	1322-1336	classification	_
5-3	1337-1343	scores	_
5-4	1344-1346	of	_
5-5	1347-1350	the	_
5-6	1351-1355	FDRs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
5-7	1356-1359	and	_
5-8	1360-1368	patients	_
5-9	1369-1373	were	_
5-10	1374-1384	negatively	_
5-11	1385-1395	correlated	_
5-12	1396-1400	with	_
5-13	1401-1406	their	_
5-14	1407-1415	measures	_
5-15	1416-1418	of	_
5-16	1419-1428	cognitive	_
5-17	1429-1437	function	_
5-18	1438-1439	.	_

Text=FDRs identified by the classifiers as having SCZ patterns were similar to the patients, but significantly different from the controls and FDRs with normal patterns in terms of their cognitive measures.
6-1	1440-1444	FDRs	_
6-2	1445-1455	identified	_
6-3	1456-1458	by	_
6-4	1459-1462	the	_
6-5	1463-1474	classifiers	_
6-6	1475-1477	as	_
6-7	1478-1484	having	_
6-8	1485-1488	SCZ	_
6-9	1489-1497	patterns	_
6-10	1498-1502	were	_
6-11	1503-1510	similar	_
6-12	1511-1513	to	_
6-13	1514-1517	the	_
6-14	1518-1526	patients	_
6-15	1527-1528	,	_
6-16	1529-1532	but	_
6-17	1533-1546	significantly	_
6-18	1547-1556	different	_
6-19	1557-1561	from	_
6-20	1562-1565	the	_
6-21	1566-1574	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-22	1575-1578	and	_
6-23	1579-1583	FDRs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
6-24	1584-1588	with	_
6-25	1589-1595	normal	_
6-26	1596-1604	patterns	_
6-27	1605-1607	in	_
6-28	1608-1613	terms	_
6-29	1614-1616	of	_
6-30	1617-1622	their	_
6-31	1623-1632	cognitive	_
6-32	1633-1641	measures	_
6-33	1642-1643	.	_

Text=These results demonstrate that the pattern classifiers built upon the informative FNs can serve as biomarkers for quantifying brain alterations in schizophrenia and help to identify FDRs with FN patterns and cognitive impairment similar to those of SCZ patients.
7-1	1644-1649	These	_
7-2	1650-1657	results	_
7-3	1658-1669	demonstrate	_
7-4	1670-1674	that	_
7-5	1675-1678	the	_
7-6	1679-1686	pattern	_
7-7	1687-1698	classifiers	_
7-8	1699-1704	built	_
7-9	1705-1709	upon	_
7-10	1710-1713	the	_
7-11	1714-1725	informative	_
7-12	1726-1729	FNs	_
7-13	1730-1733	can	_
7-14	1734-1739	serve	_
7-15	1740-1742	as	_
7-16	1743-1753	biomarkers	_
7-17	1754-1757	for	_
7-18	1758-1769	quantifying	_
7-19	1770-1775	brain	_
7-20	1776-1787	alterations	_
7-21	1788-1790	in	_
7-22	1791-1804	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-23	1805-1808	and	_
7-24	1809-1813	help	_
7-25	1814-1816	to	_
7-26	1817-1825	identify	_
7-27	1826-1830	FDRs	_
7-28	1831-1835	with	_
7-29	1836-1838	FN	_
7-30	1839-1847	patterns	_
7-31	1848-1851	and	_
7-32	1852-1861	cognitive	_
7-33	1862-1872	impairment	_
7-34	1873-1880	similar	_
7-35	1881-1883	to	_
7-36	1884-1889	those	_
7-37	1890-1892	of	_
7-38	1893-1896	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-39	1897-1905	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-40	1906-1907	.	_

Text=Methods and Materials Participants The study included 60 SCZ patients, 43 unaffected FDRs of patients (18 siblings, 15 sons/daughters, and 10 parents), and 50 healthy controls.
8-1	1908-1915	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
8-2	1916-1919	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
8-3	1920-1929	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
8-4	1930-1942	Participants	_
8-5	1943-1946	The	_
8-6	1947-1952	study	_
8-7	1953-1961	included	_
8-8	1962-1964	60	_
8-9	1965-1968	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-10	1969-1977	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-11	1978-1979	,	_
8-12	1980-1982	43	_
8-13	1983-1993	unaffected	_
8-14	1994-1998	FDRs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
8-15	1999-2001	of	_
8-16	2002-2010	patients	_
8-17	2011-2012	(	_
8-18	2013-2015	18	_
8-19	2016-2024	siblings	_
8-20	2025-2026	,	_
8-21	2027-2029	15	_
8-22	2030-2044	sons/daughters	_
8-23	2045-2046	,	_
8-24	2047-2050	and	_
8-25	2051-2053	10	_
8-26	2054-2061	parents	_
8-27	2062-2063	)	_
8-28	2064-2065	,	_
8-29	2066-2069	and	_
8-30	2070-2072	50	_
8-31	2073-2080	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
8-32	2081-2089	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
8-33	2090-2091	.	_

Text=Of the 43 unaffected FDRs, 10 were relatives of the patients recruited in this study.
9-1	2092-2094	Of	_
9-2	2095-2098	the	_
9-3	2099-2101	43	_
9-4	2102-2112	unaffected	_
9-5	2113-2117	FDRs	_
9-6	2118-2119	,	_
9-7	2120-2122	10	_
9-8	2123-2127	were	_
9-9	2128-2137	relatives	_
9-10	2138-2140	of	_
9-11	2141-2144	the	_
9-12	2145-2153	patients	_
9-13	2154-2163	recruited	_
9-14	2164-2166	in	_
9-15	2167-2171	this	_
9-16	2172-2177	study	_
9-17	2178-2179	.	_

Text=An independent dataset of 40 patients and 40 controls was used as a validation cohort to evaluate the performance of classifiers developed in our study (see Supplementary material for details).
10-1	2180-2182	An	_
10-2	2183-2194	independent	_
10-3	2195-2202	dataset	_
10-4	2203-2205	of	_
10-5	2206-2208	40	_
10-6	2209-2217	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-7	2218-2221	and	_
10-8	2222-2224	40	_
10-9	2225-2233	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-10	2234-2237	was	_
10-11	2238-2242	used	_
10-12	2243-2245	as	_
10-13	2246-2247	a	_
10-14	2248-2258	validation	_
10-15	2259-2265	cohort	_
10-16	2266-2268	to	_
10-17	2269-2277	evaluate	_
10-18	2278-2281	the	_
10-19	2282-2293	performance	_
10-20	2294-2296	of	_
10-21	2297-2308	classifiers	_
10-22	2309-2318	developed	_
10-23	2319-2321	in	_
10-24	2322-2325	our	_
10-25	2326-2331	study	_
10-26	2332-2333	(	_
10-27	2334-2337	see	_
10-28	2338-2351	Supplementary	_
10-29	2352-2360	material	_
10-30	2361-2364	for	_
10-31	2365-2372	details	_
10-32	2373-2374	)	_
10-33	2375-2376	.	_

Text=All participants provided written informed consent and the protocol was approved by the Ethics Committee of Beijing Hui-Long-Guan Hospital, Beijing, China.
11-1	2377-2380	All	_
11-2	2381-2393	participants	_
11-3	2394-2402	provided	_
11-4	2403-2410	written	_
11-5	2411-2419	informed	_
11-6	2420-2427	consent	_
11-7	2428-2431	and	_
11-8	2432-2435	the	_
11-9	2436-2444	protocol	_
11-10	2445-2448	was	_
11-11	2449-2457	approved	_
11-12	2458-2460	by	_
11-13	2461-2464	the	_
11-14	2465-2471	Ethics	_
11-15	2472-2481	Committee	_
11-16	2482-2484	of	_
11-17	2485-2492	Beijing	_
11-18	2493-2506	Hui-Long-Guan	_
11-19	2507-2515	Hospital	_
11-20	2516-2517	,	_
11-21	2518-2525	Beijing	_
11-22	2526-2527	,	_
11-23	2528-2533	China	_
11-24	2534-2535	.	_

Text=Participants were interviewed with the Structured Clinical Interview of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR) axis I disorders (SCID-I, Chinese version).
12-1	2536-2548	Participants	_
12-2	2549-2553	were	_
12-3	2554-2565	interviewed	_
12-4	2566-2570	with	_
12-5	2571-2574	the	_
12-6	2575-2585	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-7	2586-2594	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-8	2595-2604	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-9	2605-2607	of	_
12-10	2608-2611	the	_
12-11	2612-2622	Diagnostic	_
12-12	2623-2626	and	_
12-13	2627-2638	Statistical	_
12-14	2639-2645	Manual	_
12-15	2646-2648	of	_
12-16	2649-2655	Mental	_
12-17	2656-2665	Disorders	_
12-18	2666-2667	,	_
12-19	2668-2671	4th	_
12-20	2672-2679	edition	_
12-21	2680-2681	,	_
12-22	2682-2686	text	_
12-23	2687-2695	revision	_
12-24	2696-2697	(	_
12-25	2698-2707	DSM-IV-TR	_
12-26	2708-2709	)	_
12-27	2710-2714	axis	_
12-28	2715-2716	I	_
12-29	2717-2726	disorders	_
12-30	2727-2728	(	_
12-31	2729-2735	SCID-I	_
12-32	2736-2737	,	_
12-33	2738-2745	Chinese	_
12-34	2746-2753	version	_
12-35	2754-2755	)	_
12-36	2756-2757	.	_

Text=Based on interviews and reviews of clinical history, patients who met the DSM-IV-TR criteria for SCZ were included.
13-1	2758-2763	Based	_
13-2	2764-2766	on	_
13-3	2767-2777	interviews	_
13-4	2778-2781	and	_
13-5	2782-2789	reviews	_
13-6	2790-2792	of	_
13-7	2793-2801	clinical	_
13-8	2802-2809	history	_
13-9	2810-2811	,	_
13-10	2812-2820	patients	_
13-11	2821-2824	who	_
13-12	2825-2828	met	_
13-13	2829-2832	the	_
13-14	2833-2842	DSM-IV-TR	_
13-15	2843-2851	criteria	_
13-16	2852-2855	for	_
13-17	2856-2859	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
13-18	2860-2864	were	_
13-19	2865-2873	included	_
13-20	2874-2875	.	_

Text=FDRs were excluded for Axis I psychopathology and all FDRs included in this study did not have personal history of Axis I disorders according to SCID-I.
14-1	2876-2880	FDRs	_
14-2	2881-2885	were	_
14-3	2886-2894	excluded	_
14-4	2895-2898	for	_
14-5	2899-2903	Axis	_
14-6	2904-2905	I	_
14-7	2906-2921	psychopathology	_
14-8	2922-2925	and	_
14-9	2926-2929	all	_
14-10	2930-2934	FDRs	_
14-11	2935-2943	included	_
14-12	2944-2946	in	_
14-13	2947-2951	this	_
14-14	2952-2957	study	_
14-15	2958-2961	did	_
14-16	2962-2965	not	_
14-17	2966-2970	have	_
14-18	2971-2979	personal	_
14-19	2980-2987	history	_
14-20	2988-2990	of	_
14-21	2991-2995	Axis	_
14-22	2996-2997	I	_
14-23	2998-3007	disorders	_
14-24	3008-3017	according	_
14-25	3018-3020	to	_
14-26	3021-3027	SCID-I	_
14-27	3028-3029	.	_

Text=The controls did not have family history of SCZ, personal psychiatric, or neurological disorder.
15-1	3030-3033	The	_
15-2	3034-3042	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-3	3043-3046	did	_
15-4	3047-3050	not	_
15-5	3051-3055	have	_
15-6	3056-3062	family	_
15-7	3063-3070	history	_
15-8	3071-3073	of	_
15-9	3074-3077	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
15-10	3078-3079	,	_
15-11	3080-3088	personal	_
15-12	3089-3100	psychiatric	_
15-13	3101-3102	,	_
15-14	3103-3105	or	_
15-15	3106-3118	neurological	_
15-16	3119-3127	disorder	_
15-17	3128-3129	.	_

Text=The following exclusion criteria were applied to all groups: (a) <18 or> 45 years of age; (b) left-handedness; (c) history of brain trauma with loss of consciousness, neurological diseases, or serious physical diseases (such as respiratory disorders and cardiovascular disease); (d) diagnosis of alcohol/substance abuse within 12 months before participation; and (e) contraindications for MRI scan.
16-1	3130-3133	The	_
16-2	3134-3143	following	_
16-3	3144-3153	exclusion	_
16-4	3154-3162	criteria	_
16-5	3163-3167	were	_
16-6	3168-3175	applied	_
16-7	3176-3178	to	_
16-8	3179-3182	all	_
16-9	3183-3189	groups	_
16-10	3190-3191	:	_
16-11	3192-3193	(	_
16-12	3194-3195	a	_
16-13	3196-3197	)	_
16-14	3198-3199	<	_
16-15	3200-3202	18	_
16-16	3203-3205	or	_
16-17	3206-3207	>	_
16-18	3208-3210	45	_
16-19	3211-3216	years	_
16-20	3217-3219	of	_
16-21	3220-3223	age	_
16-22	3224-3225	;	_
16-23	3226-3227	(	_
16-24	3228-3229	b	_
16-25	3230-3231	)	_
16-26	3232-3247	left-handedness	_
16-27	3248-3249	;	_
16-28	3250-3251	(	_
16-29	3252-3253	c	_
16-30	3254-3255	)	_
16-31	3256-3263	history	_
16-32	3264-3266	of	_
16-33	3267-3272	brain	_
16-34	3273-3279	trauma	_
16-35	3280-3284	with	_
16-36	3285-3289	loss	_
16-37	3290-3292	of	_
16-38	3293-3306	consciousness	_
16-39	3307-3308	,	_
16-40	3309-3321	neurological	_
16-41	3322-3330	diseases	_
16-42	3331-3332	,	_
16-43	3333-3335	or	_
16-44	3336-3343	serious	_
16-45	3344-3352	physical	_
16-46	3353-3361	diseases	_
16-47	3362-3363	(	_
16-48	3364-3368	such	_
16-49	3369-3371	as	_
16-50	3372-3383	respiratory	_
16-51	3384-3393	disorders	_
16-52	3394-3397	and	_
16-53	3398-3412	cardiovascular	_
16-54	3413-3420	disease	_
16-55	3421-3422	)	_
16-56	3423-3424	;	_
16-57	3425-3426	(	_
16-58	3427-3428	d	_
16-59	3429-3430	)	_
16-60	3431-3440	diagnosis	_
16-61	3441-3443	of	_
16-62	3444-3461	alcohol/substance	_
16-63	3462-3467	abuse	_
16-64	3468-3474	within	_
16-65	3475-3477	12	_
16-66	3478-3484	months	_
16-67	3485-3491	before	_
16-68	3492-3505	participation	_
16-69	3506-3507	;	_
16-70	3508-3511	and	_
16-71	3512-3513	(	_
16-72	3514-3515	e	_
16-73	3516-3517	)	_
16-74	3518-3535	contraindications	_
16-75	3536-3539	for	_
16-76	3540-3543	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
16-77	3544-3548	scan	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
16-78	3549-3550	.	_

Text=SCZ patients were also evaluated with the Positive and Negative Syndrome Scale for symptom severity.
17-1	3551-3554	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
17-2	3555-3563	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
17-3	3564-3568	were	_
17-4	3569-3573	also	_
17-5	3574-3583	evaluated	_
17-6	3584-3588	with	_
17-7	3589-3592	the	_
17-8	3593-3601	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-9	3602-3605	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-10	3606-3614	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-11	3615-3623	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-12	3624-3629	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-13	3630-3633	for	_
17-14	3634-3641	symptom	_
17-15	3642-3650	severity	_
17-16	3651-3652	.	_

Text=In addition, cognitive function was assessed using the digit-span and digit-symbol coding tests of the Wechsler Adult Intelligence Scale in all participants.
18-1	3653-3655	In	_
18-2	3656-3664	addition	_
18-3	3665-3666	,	_
18-4	3667-3676	cognitive	_
18-5	3677-3685	function	_
18-6	3686-3689	was	_
18-7	3690-3698	assessed	_
18-8	3699-3704	using	_
18-9	3705-3708	the	_
18-10	3709-3719	digit-span	_
18-11	3720-3723	and	_
18-12	3724-3736	digit-symbol	_
18-13	3737-3743	coding	_
18-14	3744-3749	tests	_
18-15	3750-3752	of	_
18-16	3753-3756	the	_
18-17	3757-3765	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
18-18	3766-3771	Adult	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
18-19	3772-3784	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
18-20	3785-3790	Scale	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
18-21	3791-3793	in	_
18-22	3794-3797	all	_
18-23	3798-3810	participants	_
18-24	3811-3812	.	_

Text=More information on the medication histories of the patients can be found in the supplemental material.
19-1	3813-3817	More	_
19-2	3818-3829	information	_
19-3	3830-3832	on	_
19-4	3833-3836	the	_
19-5	3837-3847	medication	_
19-6	3848-3857	histories	_
19-7	3858-3860	of	_
19-8	3861-3864	the	_
19-9	3865-3873	patients	_
19-10	3874-3877	can	_
19-11	3878-3880	be	_
19-12	3881-3886	found	_
19-13	3887-3889	in	_
19-14	3890-3893	the	_
19-15	3894-3906	supplemental	_
19-16	3907-3915	material	_
19-17	3916-3917	.	_

Text=Data acquisition and preprocessing MR images were collected using a Siemens Magnetom Trio 3.0 Tesla imaging system with a standard head coil at Peking University Third Hospital.
20-1	3918-3922	Data	_
20-2	3923-3934	acquisition	_
20-3	3935-3938	and	_
20-4	3939-3952	preprocessing	_
20-5	3953-3955	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
20-6	3956-3962	images	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
20-7	3963-3967	were	_
20-8	3968-3977	collected	_
20-9	3978-3983	using	_
20-10	3984-3985	a	_
20-11	3986-3993	Siemens	_
20-12	3994-4002	Magnetom	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
20-13	4003-4007	Trio	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
20-14	4008-4011	3.0	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
20-15	4012-4017	Tesla	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
20-16	4018-4025	imaging	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
20-17	4026-4032	system	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
20-18	4033-4037	with	_
20-19	4038-4039	a	_
20-20	4040-4048	standard	_
20-21	4049-4053	head	_
20-22	4054-4058	coil	_
20-23	4059-4061	at	_
20-24	4062-4068	Peking	_
20-25	4069-4079	University	_
20-26	4080-4085	Third	_
20-27	4086-4094	Hospital	_
20-28	4095-4096	.	_

Text=For image registration, high-resolution structural T1 MRI data were acquired (256×256×192 matrix; slice thickness 1 mm; voxel resolution 1×1×1 mm3; flip angle 7°; repetition time [TR] 2530 ms; echo time [TE] 3.44 ms; inversion time 1100 ms).
21-1	4097-4100	For	_
21-2	4101-4106	image	_
21-3	4107-4119	registration	_
21-4	4120-4121	,	_
21-5	4122-4137	high-resolution	_
21-6	4138-4148	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
21-7	4149-4151	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
21-8	4152-4155	MRI	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
21-9	4156-4160	data	_
21-10	4161-4165	were	_
21-11	4166-4174	acquired	_
21-12	4175-4176	(	_
21-13	4177-4188	256×256×192	_
21-14	4189-4195	matrix	_
21-15	4196-4197	;	_
21-16	4198-4203	slice	_
21-17	4204-4213	thickness	_
21-18	4214-4215	1	_
21-19	4216-4218	mm	_
21-20	4219-4220	;	_
21-21	4221-4226	voxel	_
21-22	4227-4237	resolution	_
21-23	4238-4243	1×1×1	_
21-24	4244-4247	mm3	_
21-25	4248-4249	;	_
21-26	4250-4254	flip	_
21-27	4255-4260	angle	_
21-28	4261-4263	7°	_
21-29	4264-4265	;	_
21-30	4266-4276	repetition	_
21-31	4277-4281	time	_
21-32	4282-4283	[	_
21-33	4284-4286	TR	_
21-34	4287-4288	]	_
21-35	4289-4293	2530	_
21-36	4294-4296	ms	_
21-37	4297-4298	;	_
21-38	4299-4303	echo	_
21-39	4304-4308	time	_
21-40	4309-4310	[	_
21-41	4311-4313	TE	_
21-42	4314-4315	]	_
21-43	4316-4320	3.44	_
21-44	4321-4323	ms	_
21-45	4324-4325	;	_
21-46	4326-4335	inversion	_
21-47	4336-4340	time	_
21-48	4341-4345	1100	_
21-49	4346-4348	ms	_
21-50	4349-4350	)	_
21-51	4351-4352	.	_

Text=RsfMRI scans were obtained using a gradient-recalled echo-planar imaging sequence (field of view 220 mm, 64×64×64 matrix; TR 2000 ms; TE 30 ms; flip angle 90°; slice thickness 4 mm; voxel resolution 3.4×3.4×4.0 mm³).
22-1	4353-4359	RsfMRI	http://maven.renci.org/NeuroBridge/neurobridge#Thing
22-2	4360-4365	scans	_
22-3	4366-4370	were	_
22-4	4371-4379	obtained	_
22-5	4380-4385	using	_
22-6	4386-4387	a	_
22-7	4388-4405	gradient-recalled	_
22-8	4406-4417	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
22-9	4418-4425	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
22-10	4426-4434	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
22-11	4435-4436	(	_
22-12	4437-4442	field	_
22-13	4443-4445	of	_
22-14	4446-4450	view	_
22-15	4451-4454	220	_
22-16	4455-4457	mm	_
22-17	4458-4459	,	_
22-18	4460-4468	64×64×64	_
22-19	4469-4475	matrix	_
22-20	4476-4477	;	_
22-21	4478-4480	TR	_
22-22	4481-4485	2000	_
22-23	4486-4488	ms	_
22-24	4489-4490	;	_
22-25	4491-4493	TE	_
22-26	4494-4496	30	_
22-27	4497-4499	ms	_
22-28	4500-4501	;	_
22-29	4502-4506	flip	_
22-30	4507-4512	angle	_
22-31	4513-4516	90°	_
22-32	4517-4518	;	_
22-33	4519-4524	slice	_
22-34	4525-4534	thickness	_
22-35	4535-4536	4	_
22-36	4537-4539	mm	_
22-37	4540-4541	;	_
22-38	4542-4547	voxel	_
22-39	4548-4558	resolution	_
22-40	4559-4570	3.4×3.4×4.0	_
22-41	4571-4574	mm³	_
22-42	4575-4576	)	_
22-43	4577-4578	.	_

Text=Each rsfMRI scan had 240 volumes of 33 axial slices.
23-1	4579-4583	Each	_
23-2	4584-4590	rsfMRI	http://maven.renci.org/NeuroBridge/neurobridge#Thing
23-3	4591-4595	scan	_
23-4	4596-4599	had	_
23-5	4600-4603	240	_
23-6	4604-4611	volumes	_
23-7	4612-4614	of	_
23-8	4615-4617	33	_
23-9	4618-4623	axial	_
23-10	4624-4630	slices	_
23-11	4631-4632	.	_

Text=During acquisition, participants were instructed to close their eyes, relax, and remain awake.
24-1	4633-4639	During	_
24-2	4640-4651	acquisition	_
24-3	4652-4653	,	_
24-4	4654-4666	participants	_
24-5	4667-4671	were	_
24-6	4672-4682	instructed	_
24-7	4683-4685	to	_
24-8	4686-4691	close	_
24-9	4692-4697	their	_
24-10	4698-4702	eyes	_
24-11	4703-4704	,	_
24-12	4705-4710	relax	_
24-13	4711-4712	,	_
24-14	4713-4716	and	_
24-15	4717-4723	remain	_
24-16	4724-4729	awake	_
24-17	4730-4731	.	_

Text=All images were visually checked for artefacts, structural abnormalities, and pathologies by neuroradiologists.
25-1	4732-4735	All	_
25-2	4736-4742	images	_
25-3	4743-4747	were	_
25-4	4748-4756	visually	_
25-5	4757-4764	checked	_
25-6	4765-4768	for	_
25-7	4769-4778	artefacts	_
25-8	4779-4780	,	_
25-9	4781-4791	structural	_
25-10	4792-4805	abnormalities	_
25-11	4806-4807	,	_
25-12	4808-4811	and	_
25-13	4812-4823	pathologies	_
25-14	4824-4826	by	_
25-15	4827-4844	neuroradiologists	_
25-16	4845-4846	.	_

Text=Frame-wise displacement (FD) was calculated to measure volume-to-volume changes in head position.
26-1	4847-4857	Frame-wise	_
26-2	4858-4870	displacement	_
26-3	4871-4872	(	_
26-4	4873-4875	FD	_
26-5	4876-4877	)	_
26-6	4878-4881	was	_
26-7	4882-4892	calculated	_
26-8	4893-4895	to	_
26-9	4896-4903	measure	_
26-10	4904-4920	volume-to-volume	_
26-11	4921-4928	changes	_
26-12	4929-4931	in	_
26-13	4932-4936	head	_
26-14	4937-4945	position	_
26-15	4946-4947	.	_

Text=Thirty-seven participants were excluded because of large head-movements (mean FD> 0.5 mm).
27-1	4948-4960	Thirty-seven	_
27-2	4961-4973	participants	_
27-3	4974-4978	were	_
27-4	4979-4987	excluded	_
27-5	4988-4995	because	_
27-6	4996-4998	of	_
27-7	4999-5004	large	_
27-8	5005-5019	head-movements	_
27-9	5020-5021	(	_
27-10	5022-5026	mean	_
27-11	5027-5029	FD	_
27-12	5030-5031	>	_
27-13	5032-5035	0.5	_
27-14	5036-5038	mm	_
27-15	5039-5040	)	_
27-16	5041-5042	.	_

Text=The final sample comprised 40 controls, 34 FDRs, and 42 SCZ patients.
28-1	5043-5046	The	_
28-2	5047-5052	final	_
28-3	5053-5059	sample	_
28-4	5060-5069	comprised	_
28-5	5070-5072	40	_
28-6	5073-5081	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
28-7	5082-5083	,	_
28-8	5084-5086	34	_
28-9	5087-5091	FDRs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
28-10	5092-5093	,	_
28-11	5094-5097	and	_
28-12	5098-5100	42	_
28-13	5101-5104	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
28-14	5105-5113	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
28-15	5114-5115	.	_

Text=The preprocessing steps are outlined in the supplemental material.
29-1	5116-5119	The	_
29-2	5120-5133	preprocessing	_
29-3	5134-5139	steps	_
29-4	5140-5143	are	_
29-5	5144-5152	outlined	_
29-6	5153-5155	in	_
29-7	5156-5159	the	_
29-8	5160-5172	supplemental	_
29-9	5173-5181	material	_
29-10	5182-5183	.	_

Text=Identification of informative functional networks in schizophrenia Independent component analysis guided by group information (GIG-ICA) was adopted to extract subject-specific FNs from the rsfMRI data of patients, unaffected FDRs, and controls.
30-1	5184-5198	Identification	_
30-2	5199-5201	of	_
30-3	5202-5213	informative	_
30-4	5214-5224	functional	_
30-5	5225-5233	networks	_
30-6	5234-5236	in	_
30-7	5237-5250	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
30-8	5251-5262	Independent	_
30-9	5263-5272	component	_
30-10	5273-5281	analysis	_
30-11	5282-5288	guided	_
30-12	5289-5291	by	_
30-13	5292-5297	group	_
30-14	5298-5309	information	_
30-15	5310-5311	(	_
30-16	5312-5319	GIG-ICA	_
30-17	5320-5321	)	_
30-18	5322-5325	was	_
30-19	5326-5333	adopted	_
30-20	5334-5336	to	_
30-21	5337-5344	extract	_
30-22	5345-5361	subject-specific	_
30-23	5362-5365	FNs	_
30-24	5366-5370	from	_
30-25	5371-5374	the	_
30-26	5375-5381	rsfMRI	_
30-27	5382-5386	data	_
30-28	5387-5389	of	_
30-29	5390-5398	patients	_
30-30	5399-5400	,	_
30-31	5401-5411	unaffected	_
30-32	5412-5416	FDRs	_
30-33	5417-5418	,	_
30-34	5419-5422	and	_
30-35	5423-5431	controls	_
30-36	5432-5433	.	_

Text=The number of independent components (ICs) was estimated automatically to be 15, based on 10 randomly selected controls and 10 randomly selected SCZ patients for computing group-level ICs using FSL Melodic with its default setting of Laplace approximation to the evidence of the model order.
31-1	5434-5437	The	_
31-2	5438-5444	number	_
31-3	5445-5447	of	_
31-4	5448-5459	independent	_
31-5	5460-5470	components	_
31-6	5471-5472	(	_
31-7	5473-5476	ICs	_
31-8	5477-5478	)	_
31-9	5479-5482	was	_
31-10	5483-5492	estimated	_
31-11	5493-5506	automatically	_
31-12	5507-5509	to	_
31-13	5510-5512	be	_
31-14	5513-5515	15	_
31-15	5516-5517	,	_
31-16	5518-5523	based	_
31-17	5524-5526	on	_
31-18	5527-5529	10	_
31-19	5530-5538	randomly	_
31-20	5539-5547	selected	_
31-21	5548-5556	controls	_
31-22	5557-5560	and	_
31-23	5561-5563	10	_
31-24	5564-5572	randomly	_
31-25	5573-5581	selected	_
31-26	5582-5585	SCZ	_
31-27	5586-5594	patients	_
31-28	5595-5598	for	_
31-29	5599-5608	computing	_
31-30	5609-5620	group-level	_
31-31	5621-5624	ICs	_
31-32	5625-5630	using	_
31-33	5631-5634	FSL	_
31-34	5635-5642	Melodic	_
31-35	5643-5647	with	_
31-36	5648-5651	its	_
31-37	5652-5659	default	_
31-38	5660-5667	setting	_
31-39	5668-5670	of	_
31-40	5671-5678	Laplace	_
31-41	5679-5692	approximation	_
31-42	5693-5695	to	_
31-43	5696-5699	the	_
31-44	5700-5708	evidence	_
31-45	5709-5711	of	_
31-46	5712-5715	the	_
31-47	5716-5721	model	_
31-48	5722-5727	order	_
31-49	5728-5729	.	_

Text=The resulting group-level ICs were then used as guidance information to compute the ICs of the remaining participants using GIG-ICA, finally each subject was characterized with 15 FNs (supplemental Figure S1).
32-1	5730-5733	The	_
32-2	5734-5743	resulting	_
32-3	5744-5755	group-level	_
32-4	5756-5759	ICs	_
32-5	5760-5764	were	_
32-6	5765-5769	then	_
32-7	5770-5774	used	_
32-8	5775-5777	as	_
32-9	5778-5786	guidance	_
32-10	5787-5798	information	_
32-11	5799-5801	to	_
32-12	5802-5809	compute	_
32-13	5810-5813	the	_
32-14	5814-5817	ICs	_
32-15	5818-5820	of	_
32-16	5821-5824	the	_
32-17	5825-5834	remaining	_
32-18	5835-5847	participants	_
32-19	5848-5853	using	_
32-20	5854-5861	GIG-ICA	_
32-21	5862-5863	,	_
32-22	5864-5871	finally	_
32-23	5872-5876	each	_
32-24	5877-5884	subject	_
32-25	5885-5888	was	_
32-26	5889-5902	characterized	_
32-27	5903-5907	with	_
32-28	5908-5910	15	_
32-29	5911-5914	FNs	_
32-30	5915-5916	(	_
32-31	5917-5929	supplemental	_
32-32	5930-5936	Figure	_
32-33	5937-5939	S1	_
32-34	5940-5941	)	_
32-35	5942-5943	.	_

Text=Particularly, we used a gray matter mask in ICA in order to minimize the partial volume effects of cerebrospinal fluid and spurious effects on connectivity measures, as well as to increase the sensitivity to BOLD signal changes.
33-1	5944-5956	Particularly	_
33-2	5957-5958	,	_
33-3	5959-5961	we	_
33-4	5962-5966	used	_
33-5	5967-5968	a	_
33-6	5969-5973	gray	_
33-7	5974-5980	matter	_
33-8	5981-5985	mask	_
33-9	5986-5988	in	_
33-10	5989-5992	ICA	_
33-11	5993-5995	in	_
33-12	5996-6001	order	_
33-13	6002-6004	to	_
33-14	6005-6013	minimize	_
33-15	6014-6017	the	_
33-16	6018-6025	partial	_
33-17	6026-6032	volume	_
33-18	6033-6040	effects	_
33-19	6041-6043	of	_
33-20	6044-6057	cerebrospinal	_
33-21	6058-6063	fluid	_
33-22	6064-6067	and	_
33-23	6068-6076	spurious	_
33-24	6077-6084	effects	_
33-25	6085-6087	on	_
33-26	6088-6100	connectivity	_
33-27	6101-6109	measures	_
33-28	6110-6111	,	_
33-29	6112-6114	as	_
33-30	6115-6119	well	_
33-31	6120-6122	as	_
33-32	6123-6125	to	_
33-33	6126-6134	increase	_
33-34	6135-6138	the	_
33-35	6139-6150	sensitivity	_
33-36	6151-6153	to	_
33-37	6154-6158	BOLD	_
33-38	6159-6165	signal	_
33-39	6166-6173	changes	_
33-40	6174-6175	.	_

Text=A pattern classification method was used to identify informative FNs and build SVM classifiers to distinguish 32 patients from 30 controls who were not included in the computation of group-level ICs.
34-1	6176-6177	A	_
34-2	6178-6185	pattern	_
34-3	6186-6200	classification	_
34-4	6201-6207	method	_
34-5	6208-6211	was	_
34-6	6212-6216	used	_
34-7	6217-6219	to	_
34-8	6220-6228	identify	_
34-9	6229-6240	informative	_
34-10	6241-6244	FNs	_
34-11	6245-6248	and	_
34-12	6249-6254	build	_
34-13	6255-6258	SVM	_
34-14	6259-6270	classifiers	_
34-15	6271-6273	to	_
34-16	6274-6285	distinguish	_
34-17	6286-6288	32	_
34-18	6289-6297	patients	_
34-19	6298-6302	from	_
34-20	6303-6305	30	_
34-21	6306-6314	controls	_
34-22	6315-6318	who	_
34-23	6319-6323	were	_
34-24	6324-6327	not	_
34-25	6328-6336	included	_
34-26	6337-6339	in	_
34-27	6340-6343	the	_
34-28	6344-6355	computation	_
34-29	6356-6358	of	_
34-30	6359-6370	group-level	_
34-31	6371-6374	ICs	_
34-32	6375-6376	.	_

Text=Particularly, we built classifiers on a subset of FNs that were selected to optimize the classification performance for distinguishing SCZs from HCs using an SVM classification algorithm.
35-1	6377-6389	Particularly	_
35-2	6390-6391	,	_
35-3	6392-6394	we	_
35-4	6395-6400	built	_
35-5	6401-6412	classifiers	_
35-6	6413-6415	on	_
35-7	6416-6417	a	_
35-8	6418-6424	subset	_
35-9	6425-6427	of	_
35-10	6428-6431	FNs	_
35-11	6432-6436	that	_
35-12	6437-6441	were	_
35-13	6442-6450	selected	_
35-14	6451-6453	to	_
35-15	6454-6462	optimize	_
35-16	6463-6466	the	_
35-17	6467-6481	classification	_
35-18	6482-6493	performance	_
35-19	6494-6497	for	_
35-20	6498-6512	distinguishing	_
35-21	6513-6517	SCZs	_
35-22	6518-6522	from	_
35-23	6523-6526	HCs	_
35-24	6527-6532	using	_
35-25	6533-6535	an	_
35-26	6536-6539	SVM	_
35-27	6540-6554	classification	_
35-28	6555-6564	algorithm	_
35-29	6565-6566	.	_

Text=The SVM classification was based on similarity measures between subjects computed based on their FNs.
36-1	6567-6570	The	_
36-2	6571-6574	SVM	_
36-3	6575-6589	classification	_
36-4	6590-6593	was	_
36-5	6594-6599	based	_
36-6	6600-6602	on	_
36-7	6603-6613	similarity	_
36-8	6614-6622	measures	_
36-9	6623-6630	between	_
36-10	6631-6639	subjects	_
36-11	6640-6648	computed	_
36-12	6649-6654	based	_
36-13	6655-6657	on	_
36-14	6658-6663	their	_
36-15	6664-6667	FNs	_
36-16	6668-6669	.	_

Text=A forward component selection technique was adopted to identify the most discriminative set of FNs using following procedure.
37-1	6670-6671	A	_
37-2	6672-6679	forward	_
37-3	6680-6689	component	_
37-4	6690-6699	selection	_
37-5	6700-6709	technique	_
37-6	6710-6713	was	_
37-7	6714-6721	adopted	_
37-8	6722-6724	to	_
37-9	6725-6733	identify	_
37-10	6734-6737	the	_
37-11	6738-6742	most	_
37-12	6743-6757	discriminative	_
37-13	6758-6761	set	_
37-14	6762-6764	of	_
37-15	6765-6768	FNs	_
37-16	6769-6774	using	_
37-17	6775-6784	following	_
37-18	6785-6794	procedure	_
37-19	6795-6796	.	_

Text=Classifiers were first built on individual FNs, one for each FN, then the classifiers were evaluated with a leave-one-out (LOO) cross-validation, and finally the FN with the best classification performance was selected to be included in the classification.
38-1	6797-6808	Classifiers	_
38-2	6809-6813	were	_
38-3	6814-6819	first	_
38-4	6820-6825	built	_
38-5	6826-6828	on	_
38-6	6829-6839	individual	_
38-7	6840-6843	FNs	_
38-8	6844-6845	,	_
38-9	6846-6849	one	_
38-10	6850-6853	for	_
38-11	6854-6858	each	_
38-12	6859-6861	FN	_
38-13	6862-6863	,	_
38-14	6864-6868	then	_
38-15	6869-6872	the	_
38-16	6873-6884	classifiers	_
38-17	6885-6889	were	_
38-18	6890-6899	evaluated	_
38-19	6900-6904	with	_
38-20	6905-6906	a	_
38-21	6907-6920	leave-one-out	_
38-22	6921-6922	(	_
38-23	6923-6926	LOO	_
38-24	6927-6928	)	_
38-25	6929-6945	cross-validation	_
38-26	6946-6947	,	_
38-27	6948-6951	and	_
38-28	6952-6959	finally	_
38-29	6960-6963	the	_
38-30	6964-6966	FN	_
38-31	6967-6971	with	_
38-32	6972-6975	the	_
38-33	6976-6980	best	_
38-34	6981-6995	classification	_
38-35	6996-7007	performance	_
38-36	7008-7011	was	_
38-37	7012-7020	selected	_
38-38	7021-7023	to	_
38-39	7024-7026	be	_
38-40	7027-7035	included	_
38-41	7036-7038	in	_
38-42	7039-7042	the	_
38-43	7043-7057	classification	_
38-44	7058-7059	.	_

Text=By combining the first selected FN and one of the other FNs, a classifier could be built upon two FNs.
39-1	7060-7062	By	_
39-2	7063-7072	combining	_
39-3	7073-7076	the	_
39-4	7077-7082	first	_
39-5	7083-7091	selected	_
39-6	7092-7094	FN	_
39-7	7095-7098	and	_
39-8	7099-7102	one	_
39-9	7103-7105	of	_
39-10	7106-7109	the	_
39-11	7110-7115	other	_
39-12	7116-7119	FNs	_
39-13	7120-7121	,	_
39-14	7122-7123	a	_
39-15	7124-7134	classifier	_
39-16	7135-7140	could	_
39-17	7141-7143	be	_
39-18	7144-7149	built	_
39-19	7150-7154	upon	_
39-20	7155-7158	two	_
39-21	7159-7162	FNs	_
39-22	7163-7164	.	_

Text=All classifiers built on two FNs were then evaluated using the same LOO cross‐validation, and the FNs with the best classification performance were selected to be included in the classification.
40-1	7165-7168	All	_
40-2	7169-7180	classifiers	_
40-3	7181-7186	built	_
40-4	7187-7189	on	_
40-5	7190-7193	two	_
40-6	7194-7197	FNs	_
40-7	7198-7202	were	_
40-8	7203-7207	then	_
40-9	7208-7217	evaluated	_
40-10	7218-7223	using	_
40-11	7224-7227	the	_
40-12	7228-7232	same	_
40-13	7233-7236	LOO	_
40-14	7237-7253	cross‐validation	_
40-15	7254-7255	,	_
40-16	7256-7259	and	_
40-17	7260-7263	the	_
40-18	7264-7267	FNs	_
40-19	7268-7272	with	_
40-20	7273-7276	the	_
40-21	7277-7281	best	_
40-22	7282-7296	classification	_
40-23	7297-7308	performance	_
40-24	7309-7313	were	_
40-25	7314-7322	selected	_
40-26	7323-7325	to	_
40-27	7326-7328	be	_
40-28	7329-7337	included	_
40-29	7338-7340	in	_
40-30	7341-7344	the	_
40-31	7345-7359	classification	_
40-32	7360-7361	.	_

Text=This procedure was repeated to include more FNs in the classification one by one until one single classifier was built upon all available FNs.
41-1	7362-7366	This	_
41-2	7367-7376	procedure	_
41-3	7377-7380	was	_
41-4	7381-7389	repeated	_
41-5	7390-7392	to	_
41-6	7393-7400	include	_
41-7	7401-7405	more	_
41-8	7406-7409	FNs	_
41-9	7410-7412	in	_
41-10	7413-7416	the	_
41-11	7417-7431	classification	_
41-12	7432-7435	one	_
41-13	7436-7438	by	_
41-14	7439-7442	one	_
41-15	7443-7448	until	_
41-16	7449-7452	one	_
41-17	7453-7459	single	_
41-18	7460-7470	classifier	_
41-19	7471-7474	was	_
41-20	7475-7480	built	_
41-21	7481-7485	upon	_
41-22	7486-7489	all	_
41-23	7490-7499	available	_
41-24	7500-7503	FNs	_
41-25	7504-7505	.	_

Text=Finally, the combination of FNs with the overall best classification performance was identified to be included in the final classification.
42-1	7506-7513	Finally	_
42-2	7514-7515	,	_
42-3	7516-7519	the	_
42-4	7520-7531	combination	_
42-5	7532-7534	of	_
42-6	7535-7538	FNs	_
42-7	7539-7543	with	_
42-8	7544-7547	the	_
42-9	7548-7555	overall	_
42-10	7556-7560	best	_
42-11	7561-7575	classification	_
42-12	7576-7587	performance	_
42-13	7588-7591	was	_
42-14	7592-7602	identified	_
42-15	7603-7605	to	_
42-16	7606-7608	be	_
42-17	7609-7617	included	_
42-18	7618-7620	in	_
42-19	7621-7624	the	_
42-20	7625-7630	final	_
42-21	7631-7645	classification	_
42-22	7646-7647	.	_

Text=The FN selection and the classifier construction were carried out based on the training data.
43-1	7648-7651	The	_
43-2	7652-7654	FN	_
43-3	7655-7664	selection	_
43-4	7665-7668	and	_
43-5	7669-7672	the	_
43-6	7673-7683	classifier	_
43-7	7684-7696	construction	_
43-8	7697-7701	were	_
43-9	7702-7709	carried	_
43-10	7710-7713	out	_
43-11	7714-7719	based	_
43-12	7720-7722	on	_
43-13	7723-7726	the	_
43-14	7727-7735	training	_
43-15	7736-7740	data	_
43-16	7741-7742	.	_

Text=In the LOO cross-validation setting, each participant was analyzed as testing data once to evaluate a sigmoid kernel SVM classifier that was built upon the data of all other subjects.
44-1	7743-7745	In	_
44-2	7746-7749	the	_
44-3	7750-7753	LOO	_
44-4	7754-7770	cross-validation	_
44-5	7771-7778	setting	_
44-6	7779-7780	,	_
44-7	7781-7785	each	_
44-8	7786-7797	participant	_
44-9	7798-7801	was	_
44-10	7802-7810	analyzed	_
44-11	7811-7813	as	_
44-12	7814-7821	testing	_
44-13	7822-7826	data	_
44-14	7827-7831	once	_
44-15	7832-7834	to	_
44-16	7835-7843	evaluate	_
44-17	7844-7845	a	_
44-18	7846-7853	sigmoid	_
44-19	7854-7860	kernel	_
44-20	7861-7864	SVM	_
44-21	7865-7875	classifier	_
44-22	7876-7880	that	_
44-23	7881-7884	was	_
44-24	7885-7890	built	_
44-25	7891-7895	upon	_
44-26	7896-7899	the	_
44-27	7900-7904	data	_
44-28	7905-7907	of	_
44-29	7908-7911	all	_
44-30	7912-7917	other	_
44-31	7918-7926	subjects	_
44-32	7927-7928	.	_

Text=To avoid bias of the classification, we applied a nested LOO procedure to optimize the parameters of the SVM classifier by tuning them and choosing an optimal combination of FNs with a forward component selection algorithm (details in supplemental material).
45-1	7929-7931	To	_
45-2	7932-7937	avoid	_
45-3	7938-7942	bias	_
45-4	7943-7945	of	_
45-5	7946-7949	the	_
45-6	7950-7964	classification	_
45-7	7965-7966	,	_
45-8	7967-7969	we	_
45-9	7970-7977	applied	_
45-10	7978-7979	a	_
45-11	7980-7986	nested	_
45-12	7987-7990	LOO	_
45-13	7991-8000	procedure	_
45-14	8001-8003	to	_
45-15	8004-8012	optimize	_
45-16	8013-8016	the	_
45-17	8017-8027	parameters	_
45-18	8028-8030	of	_
45-19	8031-8034	the	_
45-20	8035-8038	SVM	_
45-21	8039-8049	classifier	_
45-22	8050-8052	by	_
45-23	8053-8059	tuning	_
45-24	8060-8064	them	_
45-25	8065-8068	and	_
45-26	8069-8077	choosing	_
45-27	8078-8080	an	_
45-28	8081-8088	optimal	_
45-29	8089-8100	combination	_
45-30	8101-8103	of	_
45-31	8104-8107	FNs	_
45-32	8108-8112	with	_
45-33	8113-8114	a	_
45-34	8115-8122	forward	_
45-35	8123-8132	component	_
45-36	8133-8142	selection	_
45-37	8143-8152	algorithm	_
45-38	8153-8154	(	_
45-39	8155-8162	details	_
45-40	8163-8165	in	_
45-41	8166-8178	supplemental	_
45-42	8179-8187	material	_
45-43	8188-8189	)	_
45-44	8190-8191	.	_

Text=FNs with high frequency (frequency> 0.8) were defined as informative FNs.
46-1	8192-8195	FNs	_
46-2	8196-8200	with	_
46-3	8201-8205	high	_
46-4	8206-8215	frequency	_
46-5	8216-8217	(	_
46-6	8218-8227	frequency	_
46-7	8228-8229	>	_
46-8	8230-8233	0.8	_
46-9	8234-8235	)	_
46-10	8236-8240	were	_
46-11	8241-8248	defined	_
46-12	8249-8251	as	_
46-13	8252-8263	informative	_
46-14	8264-8267	FNs	_
46-15	8268-8269	.	_

Text=Based on the informative FNs of 62 subjects, the LOO cross-validation model yielded 62 SVM classifiers.
47-1	8270-8275	Based	_
47-2	8276-8278	on	_
47-3	8279-8282	the	_
47-4	8283-8294	informative	_
47-5	8295-8298	FNs	_
47-6	8299-8301	of	_
47-7	8302-8304	62	_
47-8	8305-8313	subjects	_
47-9	8314-8315	,	_
47-10	8316-8319	the	_
47-11	8320-8323	LOO	_
47-12	8324-8340	cross-validation	_
47-13	8341-8346	model	_
47-14	8347-8354	yielded	_
47-15	8355-8357	62	_
47-16	8358-8361	SVM	_
47-17	8362-8373	classifiers	_
47-18	8374-8375	.	_

Text=Each of the SVM classifiers generated a classification score which was a median value of classification scores of its nested LOO classifiers, with a positive value to indicate SCZ or a negative value to indicate normal.
48-1	8376-8380	Each	_
48-2	8381-8383	of	_
48-3	8384-8387	the	_
48-4	8388-8391	SVM	_
48-5	8392-8403	classifiers	_
48-6	8404-8413	generated	_
48-7	8414-8415	a	_
48-8	8416-8430	classification	_
48-9	8431-8436	score	_
48-10	8437-8442	which	_
48-11	8443-8446	was	_
48-12	8447-8448	a	_
48-13	8449-8455	median	_
48-14	8456-8461	value	_
48-15	8462-8464	of	_
48-16	8465-8479	classification	_
48-17	8480-8486	scores	_
48-18	8487-8489	of	_
48-19	8490-8493	its	_
48-20	8494-8500	nested	_
48-21	8501-8504	LOO	_
48-22	8505-8516	classifiers	_
48-23	8517-8518	,	_
48-24	8519-8523	with	_
48-25	8524-8525	a	_
48-26	8526-8534	positive	_
48-27	8535-8540	value	_
48-28	8541-8543	to	_
48-29	8544-8552	indicate	_
48-30	8553-8556	SCZ	_
48-31	8557-8559	or	_
48-32	8560-8561	a	_
48-33	8562-8570	negative	_
48-34	8571-8576	value	_
48-35	8577-8579	to	_
48-36	8580-8588	indicate	_
48-37	8589-8595	normal	_
48-38	8596-8597	.	_

Text=In addition to classification accuracy, sensitivity, and specificity, the receiver operating characteristic curve (ROC) and the area under the ROC (AUC) were also calculated to evaluate the classification performance.
49-1	8598-8600	In	_
49-2	8601-8609	addition	_
49-3	8610-8612	to	_
49-4	8613-8627	classification	_
49-5	8628-8636	accuracy	_
49-6	8637-8638	,	_
49-7	8639-8650	sensitivity	_
49-8	8651-8652	,	_
49-9	8653-8656	and	_
49-10	8657-8668	specificity	_
49-11	8669-8670	,	_
49-12	8671-8674	the	_
49-13	8675-8683	receiver	_
49-14	8684-8693	operating	_
49-15	8694-8708	characteristic	_
49-16	8709-8714	curve	_
49-17	8715-8716	(	_
49-18	8717-8720	ROC	_
49-19	8721-8722	)	_
49-20	8723-8726	and	_
49-21	8727-8730	the	_
49-22	8731-8735	area	_
49-23	8736-8741	under	_
49-24	8742-8745	the	_
49-25	8746-8749	ROC	_
49-26	8750-8751	(	_
49-27	8752-8755	AUC	_
49-28	8756-8757	)	_
49-29	8758-8762	were	_
49-30	8763-8767	also	_
49-31	8768-8778	calculated	_
49-32	8779-8781	to	_
49-33	8782-8790	evaluate	_
49-34	8791-8794	the	_
49-35	8795-8809	classification	_
49-36	8810-8821	performance	_
49-37	8822-8823	.	_

Text=Nonparametric permutation tests were used to estimate the statistical significance of the classification performance.
50-1	8824-8837	Nonparametric	_
50-2	8838-8849	permutation	_
50-3	8850-8855	tests	_
50-4	8856-8860	were	_
50-5	8861-8865	used	_
50-6	8866-8868	to	_
50-7	8869-8877	estimate	_
50-8	8878-8881	the	_
50-9	8882-8893	statistical	_
50-10	8894-8906	significance	_
50-11	8907-8909	of	_
50-12	8910-8913	the	_
50-13	8914-8928	classification	_
50-14	8929-8940	performance	_
50-15	8941-8942	.	_

Text=The null distribution of the classification rate was estimated for all subject-specific SVM models using 10-fold cross-validation by performing 10000 random permutation tests with subject class labels randomly permuted.
51-1	8943-8946	The	_
51-2	8947-8951	null	_
51-3	8952-8964	distribution	_
51-4	8965-8967	of	_
51-5	8968-8971	the	_
51-6	8972-8986	classification	_
51-7	8987-8991	rate	_
51-8	8992-8995	was	_
51-9	8996-9005	estimated	_
51-10	9006-9009	for	_
51-11	9010-9013	all	_
51-12	9014-9030	subject-specific	_
51-13	9031-9034	SVM	_
51-14	9035-9041	models	_
51-15	9042-9047	using	_
51-16	9048-9055	10-fold	_
51-17	9056-9072	cross-validation	_
51-18	9073-9075	by	_
51-19	9076-9086	performing	_
51-20	9087-9092	10000	_
51-21	9093-9099	random	_
51-22	9100-9111	permutation	_
51-23	9112-9117	tests	_
51-24	9118-9122	with	_
51-25	9123-9130	subject	_
51-26	9131-9136	class	_
51-27	9137-9143	labels	_
51-28	9144-9152	randomly	_
51-29	9153-9161	permuted	_
51-30	9162-9163	.	_

Text=Finally, the null distribution of the classification error was visualized as a histogram of classification rates.
52-1	9164-9171	Finally	_
52-2	9172-9173	,	_
52-3	9174-9177	the	_
52-4	9178-9182	null	_
52-5	9183-9195	distribution	_
52-6	9196-9198	of	_
52-7	9199-9202	the	_
52-8	9203-9217	classification	_
52-9	9218-9223	error	_
52-10	9224-9227	was	_
52-11	9228-9238	visualized	_
52-12	9239-9241	as	_
52-13	9242-9243	a	_
52-14	9244-9253	histogram	_
52-15	9254-9256	of	_
52-16	9257-9271	classification	_
52-17	9272-9277	rates	_
52-18	9278-9279	.	_

Text=The informative FNs were further validated in terms of their classification performance using an independent dataset (see supplemental material for details).
53-1	9280-9283	The	_
53-2	9284-9295	informative	_
53-3	9296-9299	FNs	_
53-4	9300-9304	were	_
53-5	9305-9312	further	_
53-6	9313-9322	validated	_
53-7	9323-9325	in	_
53-8	9326-9331	terms	_
53-9	9332-9334	of	_
53-10	9335-9340	their	_
53-11	9341-9355	classification	_
53-12	9356-9367	performance	_
53-13	9368-9373	using	_
53-14	9374-9376	an	_
53-15	9377-9388	independent	_
53-16	9389-9396	dataset	_
53-17	9397-9398	(	_
53-18	9399-9402	see	_
53-19	9403-9415	supplemental	_
53-20	9416-9424	material	_
53-21	9425-9428	for	_
53-22	9429-9436	details	_
53-23	9437-9438	)	_
53-24	9439-9440	.	_

Text=The LOO cross-validation classifiers were applied to the FNs of FDRs, so each FDR was given 62 individual classification scores.
54-1	9441-9444	The	_
54-2	9445-9448	LOO	_
54-3	9449-9465	cross-validation	_
54-4	9466-9477	classifiers	_
54-5	9478-9482	were	_
54-6	9483-9490	applied	_
54-7	9491-9493	to	_
54-8	9494-9497	the	_
54-9	9498-9501	FNs	_
54-10	9502-9504	of	_
54-11	9505-9509	FDRs	_
54-12	9510-9511	,	_
54-13	9512-9514	so	_
54-14	9515-9519	each	_
54-15	9520-9523	FDR	_
54-16	9524-9527	was	_
54-17	9528-9533	given	_
54-18	9534-9536	62	_
54-19	9537-9547	individual	_
54-20	9548-9562	classification	_
54-21	9563-9569	scores	_
54-22	9570-9571	.	_

Text=The median of the individual classification scores was finally used as a robust measure to characterize the affinity of each FDR to SCZ (a positive score indicates a SCZ pattern).
55-1	9572-9575	The	_
55-2	9576-9582	median	_
55-3	9583-9585	of	_
55-4	9586-9589	the	_
55-5	9590-9600	individual	_
55-6	9601-9615	classification	_
55-7	9616-9622	scores	_
55-8	9623-9626	was	_
55-9	9627-9634	finally	_
55-10	9635-9639	used	_
55-11	9640-9642	as	_
55-12	9643-9644	a	_
55-13	9645-9651	robust	_
55-14	9652-9659	measure	_
55-15	9660-9662	to	_
55-16	9663-9675	characterize	_
55-17	9676-9679	the	_
55-18	9680-9688	affinity	_
55-19	9689-9691	of	_
55-20	9692-9696	each	_
55-21	9697-9700	FDR	_
55-22	9701-9703	to	_
55-23	9704-9707	SCZ	_
55-24	9708-9709	(	_
55-25	9710-9711	a	_
55-26	9712-9720	positive	_
55-27	9721-9726	score	_
55-28	9727-9736	indicates	_
55-29	9737-9738	a	_
55-30	9739-9742	SCZ	_
55-31	9743-9750	pattern	_
55-32	9751-9752	)	_
55-33	9753-9754	.	_

Text=A flowchart of the pattern classification algorithm is shown in supplemental Figure S3.
56-1	9755-9756	A	_
56-2	9757-9766	flowchart	_
56-3	9767-9769	of	_
56-4	9770-9773	the	_
56-5	9774-9781	pattern	_
56-6	9782-9796	classification	_
56-7	9797-9806	algorithm	_
56-8	9807-9809	is	_
56-9	9810-9815	shown	_
56-10	9816-9818	in	_
56-11	9819-9831	supplemental	_
56-12	9832-9838	Figure	_
56-13	9839-9841	S3	_
56-14	9842-9843	.	_

Text=Based on the classification scores, the FDRs were classified as SCZ-specific (S-FDRs) or HC-specific (H-FDRs).
57-1	9844-9849	Based	_
57-2	9850-9852	on	_
57-3	9853-9856	the	_
57-4	9857-9871	classification	_
57-5	9872-9878	scores	_
57-6	9879-9880	,	_
57-7	9881-9884	the	_
57-8	9885-9889	FDRs	_
57-9	9890-9894	were	_
57-10	9895-9905	classified	_
57-11	9906-9908	as	_
57-12	9909-9921	SCZ-specific	_
57-13	9922-9923	(	_
57-14	9924-9930	S-FDRs	_
57-15	9931-9932	)	_
57-16	9933-9935	or	_
57-17	9936-9947	HC-specific	_
57-18	9948-9949	(	_
57-19	9950-9956	H-FDRs	_
57-20	9957-9958	)	_
57-21	9959-9960	.	_

Text=We also adopted a certainty measure to evaluate the classification reliability for each individual subject based on the LOO cross-validation classifiers.
58-1	9961-9963	We	_
58-2	9964-9968	also	_
58-3	9969-9976	adopted	_
58-4	9977-9978	a	_
58-5	9979-9988	certainty	_
58-6	9989-9996	measure	_
58-7	9997-9999	to	_
58-8	10000-10008	evaluate	_
58-9	10009-10012	the	_
58-10	10013-10027	classification	_
58-11	10028-10039	reliability	_
58-12	10040-10043	for	_
58-13	10044-10048	each	_
58-14	10049-10059	individual	_
58-15	10060-10067	subject	_
58-16	10068-10073	based	_
58-17	10074-10076	on	_
58-18	10077-10080	the	_
58-19	10081-10084	LOO	_
58-20	10085-10101	cross-validation	_
58-21	10102-10113	classifiers	_
58-22	10114-10115	.	_

Text=Particularly, the classification certainty was measured by, where np is the number of positive classification scores and n is the total number of LOO classifiers.
59-1	10116-10128	Particularly	_
59-2	10129-10130	,	_
59-3	10131-10134	the	_
59-4	10135-10149	classification	_
59-5	10150-10159	certainty	_
59-6	10160-10163	was	_
59-7	10164-10172	measured	_
59-8	10173-10175	by	_
59-9	10176-10177	,	_
59-10	10178-10183	where	_
59-11	10184-10186	np	_
59-12	10187-10189	is	_
59-13	10190-10193	the	_
59-14	10194-10200	number	_
59-15	10201-10203	of	_
59-16	10204-10212	positive	_
59-17	10213-10227	classification	_
59-18	10228-10234	scores	_
59-19	10235-10238	and	_
59-20	10239-10240	n	_
59-21	10241-10243	is	_
59-22	10244-10247	the	_
59-23	10248-10253	total	_
59-24	10254-10260	number	_
59-25	10261-10263	of	_
59-26	10264-10267	LOO	_
59-27	10268-10279	classifiers	_
59-28	10280-10281	.	_

Text=A higher value indicated a higher classification reliability, and vice versa.
60-1	10282-10283	A	_
60-2	10284-10290	higher	_
60-3	10291-10296	value	_
60-4	10297-10306	indicated	_
60-5	10307-10308	a	_
60-6	10309-10315	higher	_
60-7	10316-10330	classification	_
60-8	10331-10342	reliability	_
60-9	10343-10344	,	_
60-10	10345-10348	and	_
60-11	10349-10353	vice	_
60-12	10354-10359	versa	_
60-13	10360-10361	.	_

Text=We excluded subjects with lower classification certainty (<0.9) in post-hoc analyses.
61-1	10362-10364	We	_
61-2	10365-10373	excluded	_
61-3	10374-10382	subjects	_
61-4	10383-10387	with	_
61-5	10388-10393	lower	_
61-6	10394-10408	classification	_
61-7	10409-10418	certainty	_
61-8	10419-10420	(	_
61-9	10421-10422	<	_
61-10	10423-10426	0.9	_
61-11	10427-10428	)	_
61-12	10429-10431	in	_
61-13	10432-10440	post-hoc	_
61-14	10441-10449	analyses	_
61-15	10450-10451	.	_

Text=Finally, the sample comprised 27 controls, 33 FDRs, and 28 SCZs in the post-hoc analysis.
62-1	10452-10459	Finally	_
62-2	10460-10461	,	_
62-3	10462-10465	the	_
62-4	10466-10472	sample	_
62-5	10473-10482	comprised	_
62-6	10483-10485	27	_
62-7	10486-10494	controls	_
62-8	10495-10496	,	_
62-9	10497-10499	33	_
62-10	10500-10504	FDRs	_
62-11	10505-10506	,	_
62-12	10507-10510	and	_
62-13	10511-10513	28	_
62-14	10514-10518	SCZs	_
62-15	10519-10521	in	_
62-16	10522-10525	the	_
62-17	10526-10534	post-hoc	_
62-18	10535-10543	analysis	_
62-19	10544-10545	.	_

Text=Voxelwise functional connectivity (FC) measures of each informative FN were computed as Pearson correlation coefficients between time courses of the whole-brain voxels and the FN, and transferred to z-scores for every participant.
63-1	10546-10555	Voxelwise	_
63-2	10556-10566	functional	_
63-3	10567-10579	connectivity	_
63-4	10580-10581	(	_
63-5	10582-10584	FC	_
63-6	10585-10586	)	_
63-7	10587-10595	measures	_
63-8	10596-10598	of	_
63-9	10599-10603	each	_
63-10	10604-10615	informative	_
63-11	10616-10618	FN	_
63-12	10619-10623	were	_
63-13	10624-10632	computed	_
63-14	10633-10635	as	_
63-15	10636-10643	Pearson	_
63-16	10644-10655	correlation	_
63-17	10656-10668	coefficients	_
63-18	10669-10676	between	_
63-19	10677-10681	time	_
63-20	10682-10689	courses	_
63-21	10690-10692	of	_
63-22	10693-10696	the	_
63-23	10697-10708	whole-brain	_
63-24	10709-10715	voxels	_
63-25	10716-10719	and	_
63-26	10720-10723	the	_
63-27	10724-10726	FN	_
63-28	10727-10728	,	_
63-29	10729-10732	and	_
63-30	10733-10744	transferred	_
63-31	10745-10747	to	_
63-32	10748-10756	z-scores	_
63-33	10757-10760	for	_
63-34	10761-10766	every	_
63-35	10767-10778	participant	_
63-36	10779-10780	.	_

Text=Then, the voxelwise FC measures were compared between any two groups using statistical nonparametric mapping software (SnPM13, http: //warwick.ac.uk/snpm; p = 0.05, permutation tests n = 10000, age, sex, years of education, and FD as covariates).
64-1	10781-10785	Then	_
64-2	10786-10787	,	_
64-3	10788-10791	the	_
64-4	10792-10801	voxelwise	_
64-5	10802-10804	FC	_
64-6	10805-10813	measures	_
64-7	10814-10818	were	_
64-8	10819-10827	compared	_
64-9	10828-10835	between	_
64-10	10836-10839	any	_
64-11	10840-10843	two	_
64-12	10844-10850	groups	_
64-13	10851-10856	using	_
64-14	10857-10868	statistical	_
64-15	10869-10882	nonparametric	_
64-16	10883-10890	mapping	_
64-17	10891-10899	software	_
64-18	10900-10901	(	_
64-19	10902-10908	SnPM13	_
64-20	10909-10910	,	_
64-21	10911-10915	http	_
64-22	10916-10917	:	_
64-23	10918-10938	//warwick.ac.uk/snpm	_
64-24	10939-10940	;	_
64-25	10941-10942	p	_
64-26	10943-10944	=	_
64-27	10945-10949	0.05	_
64-28	10950-10951	,	_
64-29	10952-10963	permutation	_
64-30	10964-10969	tests	_
64-31	10970-10971	n	_
64-32	10972-10973	=	_
64-33	10974-10979	10000	_
64-34	10980-10981	,	_
64-35	10982-10985	age	_
64-36	10986-10987	,	_
64-37	10988-10991	sex	_
64-38	10992-10993	,	_
64-39	10994-10999	years	_
64-40	11000-11002	of	_
64-41	11003-11012	education	_
64-42	11013-11014	,	_
64-43	11015-11018	and	_
64-44	11019-11021	FD	_
64-45	11022-11024	as	_
64-46	11025-11035	covariates	_
64-47	11036-11037	)	_
64-48	11038-11039	.	_

Text=The comparisons were restricted to brain regions with significant FC within the FN (one sample t-test, p = 0.05, family-wise error correction, and cluster size> 100).
65-1	11040-11043	The	_
65-2	11044-11055	comparisons	_
65-3	11056-11060	were	_
65-4	11061-11071	restricted	_
65-5	11072-11074	to	_
65-6	11075-11080	brain	_
65-7	11081-11088	regions	_
65-8	11089-11093	with	_
65-9	11094-11105	significant	_
65-10	11106-11108	FC	_
65-11	11109-11115	within	_
65-12	11116-11119	the	_
65-13	11120-11122	FN	_
65-14	11123-11124	(	_
65-15	11125-11128	one	_
65-16	11129-11135	sample	_
65-17	11136-11142	t-test	_
65-18	11143-11144	,	_
65-19	11145-11146	p	_
65-20	11147-11148	=	_
65-21	11149-11153	0.05	_
65-22	11154-11155	,	_
65-23	11156-11167	family-wise	_
65-24	11168-11173	error	_
65-25	11174-11184	correction	_
65-26	11185-11186	,	_
65-27	11187-11190	and	_
65-28	11191-11198	cluster	_
65-29	11199-11203	size	_
65-30	11204-11205	>	_
65-31	11206-11209	100	_
65-32	11210-11211	)	_
65-33	11212-11213	.	_

Text=Similarity measures of informative FNs between individuals were computed based on principal angles for visualizing the similarity among FDRs, SCZs, and HCs.
66-1	11214-11224	Similarity	_
66-2	11225-11233	measures	_
66-3	11234-11236	of	_
66-4	11237-11248	informative	_
66-5	11249-11252	FNs	_
66-6	11253-11260	between	_
66-7	11261-11272	individuals	_
66-8	11273-11277	were	_
66-9	11278-11286	computed	_
66-10	11287-11292	based	_
66-11	11293-11295	on	_
66-12	11296-11305	principal	_
66-13	11306-11312	angles	_
66-14	11313-11316	for	_
66-15	11317-11328	visualizing	_
66-16	11329-11332	the	_
66-17	11333-11343	similarity	_
66-18	11344-11349	among	_
66-19	11350-11354	FDRs	_
66-20	11355-11356	,	_
66-21	11357-11361	SCZs	_
66-22	11362-11363	,	_
66-23	11364-11367	and	_
66-24	11368-11371	HCs	_
66-25	11372-11373	.	_

Text=Statistical comparisons of clinical characteristics between groups To identify functional patterns for clinical characteristics analysis, FDRs were divided into two subgroups: those with SCZ-specific classification scores> 0, and those with HC-specific classification scores ≤0 (positive scores reflect the presence of an SZC-specific functional pattern, and negative scores indicate a control-specific pattern).
67-1	11374-11385	Statistical	_
67-2	11386-11397	comparisons	_
67-3	11398-11400	of	_
67-4	11401-11409	clinical	_
67-5	11410-11425	characteristics	_
67-6	11426-11433	between	_
67-7	11434-11440	groups	_
67-8	11441-11443	To	_
67-9	11444-11452	identify	_
67-10	11453-11463	functional	_
67-11	11464-11472	patterns	_
67-12	11473-11476	for	_
67-13	11477-11485	clinical	_
67-14	11486-11501	characteristics	_
67-15	11502-11510	analysis	_
67-16	11511-11512	,	_
67-17	11513-11517	FDRs	_
67-18	11518-11522	were	_
67-19	11523-11530	divided	_
67-20	11531-11535	into	_
67-21	11536-11539	two	_
67-22	11540-11549	subgroups	_
67-23	11550-11551	:	_
67-24	11552-11557	those	_
67-25	11558-11562	with	_
67-26	11563-11575	SCZ-specific	_
67-27	11576-11590	classification	_
67-28	11591-11597	scores	_
67-29	11598-11599	>	_
67-30	11600-11601	0	_
67-31	11602-11603	,	_
67-32	11604-11607	and	_
67-33	11608-11613	those	_
67-34	11614-11618	with	_
67-35	11619-11630	HC-specific	_
67-36	11631-11645	classification	_
67-37	11646-11652	scores	_
67-38	11653-11655	≤0	_
67-39	11656-11657	(	_
67-40	11658-11666	positive	_
67-41	11667-11673	scores	_
67-42	11674-11681	reflect	_
67-43	11682-11685	the	_
67-44	11686-11694	presence	_
67-45	11695-11697	of	_
67-46	11698-11700	an	_
67-47	11701-11713	SZC-specific	_
67-48	11714-11724	functional	_
67-49	11725-11732	pattern	_
67-50	11733-11734	,	_
67-51	11735-11738	and	_
67-52	11739-11747	negative	_
67-53	11748-11754	scores	_
67-54	11755-11763	indicate	_
67-55	11764-11765	a	_
67-56	11766-11782	control-specific	_
67-57	11783-11790	pattern	_
67-58	11791-11792	)	_
67-59	11793-11794	.	_

Text=The pseudo two-sample t-test at 5% significance level (permutation tests, n = 10000) was used to quantify the statistical significance of group differences.
68-1	11795-11798	The	_
68-2	11799-11805	pseudo	_
68-3	11806-11816	two-sample	_
68-4	11817-11823	t-test	_
68-5	11824-11826	at	_
68-6	11827-11828	5	_
68-7	11829-11830	%	_
68-8	11831-11843	significance	_
68-9	11844-11849	level	_
68-10	11850-11851	(	_
68-11	11852-11863	permutation	_
68-12	11864-11869	tests	_
68-13	11870-11871	,	_
68-14	11872-11873	n	_
68-15	11874-11875	=	_
68-16	11876-11881	10000	_
68-17	11882-11883	)	_
68-18	11884-11887	was	_
68-19	11888-11892	used	_
68-20	11893-11895	to	_
68-21	11896-11904	quantify	_
68-22	11905-11908	the	_
68-23	11909-11920	statistical	_
68-24	11921-11933	significance	_
68-25	11934-11936	of	_
68-26	11937-11942	group	_
68-27	11943-11954	differences	_
68-28	11955-11956	.	_

Text=Correlation analysis between cognitive function and classification scores A general linear model with outliers removed at 95% confidence intervals was used to investigate correlations between the classification scores and measures of cognitive function in groups, with age, sex, years of education, and FD as covariates.
69-1	11957-11968	Correlation	_
69-2	11969-11977	analysis	_
69-3	11978-11985	between	_
69-4	11986-11995	cognitive	_
69-5	11996-12004	function	_
69-6	12005-12008	and	_
69-7	12009-12023	classification	_
69-8	12024-12030	scores	_
69-9	12031-12032	A	_
69-10	12033-12040	general	_
69-11	12041-12047	linear	_
69-12	12048-12053	model	_
69-13	12054-12058	with	_
69-14	12059-12067	outliers	_
69-15	12068-12075	removed	_
69-16	12076-12078	at	_
69-17	12079-12081	95	_
69-18	12082-12083	%	_
69-19	12084-12094	confidence	_
69-20	12095-12104	intervals	_
69-21	12105-12108	was	_
69-22	12109-12113	used	_
69-23	12114-12116	to	_
69-24	12117-12128	investigate	_
69-25	12129-12141	correlations	_
69-26	12142-12149	between	_
69-27	12150-12153	the	_
69-28	12154-12168	classification	_
69-29	12169-12175	scores	_
69-30	12176-12179	and	_
69-31	12180-12188	measures	_
69-32	12189-12191	of	_
69-33	12192-12201	cognitive	_
69-34	12202-12210	function	_
69-35	12211-12213	in	_
69-36	12214-12220	groups	_
69-37	12221-12222	,	_
69-38	12223-12227	with	_
69-39	12228-12231	age	_
69-40	12232-12233	,	_
69-41	12234-12237	sex	_
69-42	12238-12239	,	_
69-43	12240-12245	years	_
69-44	12246-12248	of	_
69-45	12249-12258	education	_
69-46	12259-12260	,	_
69-47	12261-12264	and	_
69-48	12265-12267	FD	_
69-49	12268-12270	as	_
69-50	12271-12281	covariates	_
69-51	12282-12283	.	_

